biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by BearDownAZon Mar 31, 2019 8:17am

133 Views

Post# 29560177

RE:RE:RE:RE:RE:RE:TrainWreck

"And to make deals, we have to show that our technology works in humans, or at least primates. The failure of the NHP trial to show brain concentration last year was a disaster. We have proof of brain concentration in mice, and the technology should therefore work in primates, let's fix the experimental design and show that it works."

I don't think that enough of the experimental design was known, nor enough of the experimental data shared, to conclude that the primate experiment was a definitive failure.

BearDownAZ

Bullboard Posts

Visionstate set to leverage success in the U.S. market